Radar · Genomics in Massachusetts
Best Genomics Companies in Massachusetts, United States
The 307 best Genomics companies in Massachusetts, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: ElevateBio.
By Riya SenguptaFinancials
307companies tracked
$18.1Bdisclosed funding
3unicorns
218have raised
FLIAR INTELLIGENCE · GENOMICS × MASSACHUSETTS
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
84%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
573kcombined LinkedIn audience
25%of audience held by top 3
9companies hiring publicly (12 mo)
Ranked: Best Genomics companies in Massachusetts
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | ElevateBio Provider of transnational research for portfolio of cell and gene therapy | $1.2B | 36 mo ago | 466 | 2018 | David Hallal Co-Founder | 13 patents RNA delivery systems and circular RNA-based cellular reprogramming therapeutics | 3 partnerships |
| 2 | Ginkgo Bioworks 🦄 Autonomous labs for biotechnology, empowering scientists to design the living world | $796M | 30 mo ago | 1,218 | 2008 | Austin Che Co-Founder | 385 patents Engineering microbes for biosynthesis of drugs, flavors, proteins, and immune therapeutics | — |
| 3 | Tessera Therapeutics Provider of new genome engineering technology for treating multiple diseases | $532M | 50 mo ago | 203 | 2017 | Robert Citorik Co-Founder & Director | — | — |
| 4 | eGenesis Developer of a gene transplantation platform for humanizing pig cells 67Funding top 20%Product top 21%Patents top 23%Moat top 28% All 11 signals ▾Fundingtop 20% Producttop 21% Patentstop 23% Moattop 28% Innovationtop 32% Growthtop 38% Talenttop 38% Techtop 40% Marketbottom 44% Globalbottom 44% Newsbottom 18% Funding: Raised $481M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Product: 5 distinct product lines · Company stage: Series D rank vs industry peers · Fliar Intelligence Index 67/100 | $481M | 21 mo ago | 94 94 → 153 (+63%) · sector median +0% | 2015 | Luhan Yang Co-Founder | 61 patents Genetically engineered livestock for xenotransplant organ compatibility | 1 award |
| 5 | Arbor Biotechnologies Provider of genomic technologies and drug discovery platform 82Patents top 15%Innovation top 17%Funding top 19%Growth top 25% All 12 signals ▾Patentstop 15% Innovationtop 17% Fundingtop 19% Growthtop 25% Producttop 25% Moattop 26% Talenttop 28% AItop 45% Markettop 47% Globalbottom 42% Techbottom 36% Newsbottom 27% Patents: 372 patents matched (strict assignee match) · 307 filings since 2022 vs 65 in 2017-21 Innovation: 372 patents (top 6% of patent-holders) · 307 filings since 2022 vs 65 in 2017-21 rank vs industry peers · Fliar Intelligence Index 82/100 | $300M | 7 mo ago | 117 117 → 102 (-13%) · sector median +0% | 2016 | David Scott Co-Founder | 372 patents CRISPR nucleases and reverse transcriptase enzymes for genome editing platforms | 2 partnerships |
| 6 | Chroma Medicine Developer of an epigenetic editing platform for genomic medicines | $260M | 40 mo ago | 122 | 2020 | Catherine Breen CEO | 62 patents Epigenetic gene‑regulation therapeutics targeting specific disease‑relevant proteins | — |
| 7 | Scipher Medicine Provider of precision medicine based on liquid biopsy test | $231M | 25 mo ago | 126 | 2014 | Joseph Loscalzo Co-Founder | 29 patents AI-driven personalized therapy monitoring and response prediction for anti‑TNF treatments | — |
| 8 | Ring Therapeutics Developer of gene therapy platform by harnessing the human commensal virome | $230M | 39 mo ago | 117 | 2018 | Tuyen Ong CEO | — | — |
| 9 | GreenLight Biosciences 🦄 Developer of a platform for RNA-based products for life science industry 69Funding top 23%Growth top 23%Patents top 24%Innovation top 29% All 11 signals ▾Fundingtop 23% Growthtop 23% Patentstop 24% Innovationtop 29% Talenttop 41% Moattop 42% Fin. healthtop 47% Markettop 48% Techbottom 44% Globalbottom 42% Newsbottom 40% Funding: Raised $215M across 12 rounds · 12 rounds over 13 yrs (0.9/yr) Growth: Headcount 163 → 287 (+76%) across vintages · Revenue +325% YoY rank vs industry peers · Fliar Intelligence Index 69/100 | $215M | 14 mo ago | 287 287 → 183 (-36%) · sector median +0% | 2008 | Andrey Zarur Co-Founder & CEO | 311 patents RNAi-based biopesticides and lipid‑encapsulated RNA delivery for crop protection | — |
| 10 | Tome Biosciences Developer of gene insertion platform for genomic medicines | $213M | 30 mo ago | 123 | 2021 | — | — | — |
| 11 | Remix Therapeutics Developer of RNA processing therapeutics to treat multiple diseases | $211M | 29 mo ago | 56 56 → 50 (-11%) · sector median +0% | 2019 | Peter Smith Co-Founder | 202 patents Small-molecule modulators of RNA splicing targeting alternative splice site regulation | 4 job openings |
| 12 | Editas Medicine Developer of therapeutics for rare genetic diseases | $210M | 29 mo ago | 257 257 → 183 (-29%) · sector median +0% | 2013 | Cynthia Collins Ex-CEO & President | 713 patents CRISPR-based gene editing therapeutics for blood disorders and immune cell engineering | — |
| 13 | Asimov Provider of integrated suite for advanced genetic design and manufacturing | $209M | 41 mo ago | 64 64 → 119 (+86%) · sector median +0% | 2017 | Chris Voigt Co-Founder | 70 patents Efficient manufacturing of recombinant viral vectors for gene therapy applications | 1 launch · 1 partnership |
| 14 | Ensoma Developer of in vivo hematopoietic stem cell engineering for genomic medicine | $205M | 37 mo ago | 52 52 → 51 (-2%) · sector median +0% | 2019 | — | 62 patents Adenoviral gene‑therapy vectors enabling multi‑lineage therapeutic expression and stem‑cell mobilization | — |
| 15 | ROME Therapeutics Developer of therapeutics for cancer and autoimmune disorders | $199M | 33 mo ago | 32 | 2020 | — | — | — |
| 16 | CAMP4 Provider of a drug prediction and development tool for researchers 53Funding top 17%Growth top 37%Moat top 39%Talent top 41% All 9 signals ▾Fundingtop 17% Growthtop 37% Moattop 39% Talenttop 41% AItop 45% Marketbottom 41% Globalbottom 37% Techbottom 26% Newsbottom 20% Funding: Raised $180M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Growth: Headcount 37 → 62 (+68%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $180M | 9 mo ago | 62 62 → 62 (+0%) · sector median +0% | 2018 | Josh Mandel-Brehm CEO | — | — |
| 17 | Tango Therapeutics Developer of drugs for the treatment of cancer 72Funding top 21%News top 21%Growth top 24%Talent top 33% All 10 signals ▾Fundingtop 21% Newstop 21% Growthtop 24% Talenttop 33% Fin. healthtop 41% Techtop 44% Markettop 45% Partnerstop 45% Moatbottom 49% Globalbottom 37% Funding: Raised $165M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) News: 17 BI events in 12 mo (of 35 tracked, 6 types) · +240% YoY rank vs industry peers · Fliar Intelligence Index 72/100 | $165M | 7 mo ago | 140 140 → 157 (+12%) · sector median +0% | 2017 | Barbara Weber Md President and CEO | — | — |
| 18 | QurAlis Developing drugs & CSF cartridge device for treating amyotrophic lateral sclerosis (ALS) 64Funding top 20%Patents top 23%Innovation top 25%Growth top 26% All 10 signals ▾Fundingtop 20% Patentstop 23% Innovationtop 25% Growthtop 26% Moattop 32% Talenttop 41% Techbottom 43% Globalbottom 42% Marketbottom 36% Newsbottom 22% Funding: Raised $144M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Patents: 69 patents matched (strict assignee match) · 62 filings since 2022 vs 7 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $144M | 9 mo ago | 38 38 → 87 (+129%) · sector median +0% | 2016 | Kasper Roet Founder & CEO | 69 patents Antisense oligonucleotide therapeutics targeting UNC13A for neurological disease treatment | — |
| 19 | Seres Therapeutics Developer of microbiome therapeutics to treat a wide range of diseases | $134M | 24 mo ago | 332 | 2010 | David Berry Founder | 274 patents Live bacterial therapeutics for gut microbiome modulation in infection and cancer treatment | — |
| 20 | Variantyx Provider of genomics data analysis platform for healthcare | $125M | 25 mo ago | 122 122 → 226 (+85%) · sector median +0% | 2014 | Haim Neerman Co-Founder & CEO | — | 3 job openings · 1 launch |
| 21 | Manus Bio Developer of phytochemicals using microbial fermentation | $125M | 36 mo ago | 104 | 2011 | Gregory Stephanopoulos Co-Founder | — | 4 job openings · 3 launchs |
| 22 | Sherlock Provider of a diagnostic platform for DNA and RNA detection 62Growth top 13%Funding top 22%Talent top 28%Moat top 41% All 9 signals ▾Growthtop 13% Fundingtop 22% Talenttop 28% Moattop 41% Patentsbottom 46% Innovationbottom 41% Marketbottom 39% Globalbottom 37% Newsbottom 34% Growth: Headcount 1 → 33 (+3200%) across vintages · Fresh capital in last 24 mo Funding: Raised $111M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $111M | 12 mo ago | 33 | 2019 | David Walt Co-Founder | 5 patents Remote health monitoring systems that detect critical vitals and trigger emergency interventions | — |
| 23 | Voyager Therapeutics Neurogenetic medicine innovator, developing transformative treatments for neurological diseases | $105M | 29 mo ago | 183 183 → 161 (-12%) · sector median +0% | 2014 | Steven Paul Co-Founder | 790 patents Engineered AAV gene therapy vectors for neurodegenerative and metabolic disorder treatment | — |
| 24 | Strand Therapeutics Provider of platform to deliver mRNA therapeutics for multi functional treatments 64Growth top 13%Funding top 24%Moat top 31%News top 41% All 7 signals ▾Growthtop 13% Fundingtop 24% Moattop 31% Newstop 41% Talenttop 41% Globalbottom 39% Marketbottom 38% Growth: Headcount 16 → 47 (+194%) across vintages · Fresh capital in last 24 mo Funding: Raised $103M across 6 rounds · 6 rounds over 7 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $103M | 12 mo ago | 47 | 2017 | Tasuku Kitada Co-founder | — | 2 awards |
| 25 | Solid Biosciences Developer of gene therapy platform for Duchenne muscular dystrophy 53Patents top 20%Funding top 24%Innovation top 31%Tech top 33% All 10 signals ▾Patentstop 20% Fundingtop 24% Innovationtop 31% Techtop 33% Moattop 38% Newstop 48% Marketbottom 49% Growthbottom 44% Globalbottom 42% Fin. healthbottom 32% Patents: 60 patents matched (strict assignee match) · 43 filings since 2022 vs 17 in 2017-21 Funding: Raised $92.5M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $92M | 3 mo ago | 101 | 2014 | — | 60 patents AAV vector manufacturing and formulation for cardiac gene therapies | — |
| 26 | Rgenta Developer of RNA-based therapeutics for multiple disorders 32Talent top 28%Funding top 29%Moat top 39%Global bottom 39% All 6 signals ▾Talenttop 28% Fundingtop 29% Moattop 39% Globalbottom 39% Marketbottom 28% Newsbottom 22% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $90.0M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $90M | 12 mo ago | 11 | 2018 | Zhiping Weng Co-Founder | — | — |
| 27 | AIRNA Developer of gene therapies for rare and common diseases | $90M | 14 mo ago | — | 2021 | Jin Li Co-Founder | 6 patents RNA editing using chemically modified antisense oligonucleotides and targeted delivery | 1 partnership |
| 28 | Ascidian Therapeutics Developer of RNA therapeutics to treat genetic diseases | $90M | 31 mo ago | 37 37 → 48 (+30%) · sector median +0% | 2020 | Michael Ehlers Founder & CEO | — | 1 job opening · 4 partnerships |
| 29 | Stylus Medicine Developer of gene-based therapeutics for multiple diseases | $85M | 13 mo ago | 21 | 2022 | — | — | — |
| 30 | GCTx Developer of a synthetic biology platform for cell programming | $75M | 20 mo ago | 15 | 2019 | Cory Smith Scientific Co-Founder and Head of Discovery Platforms | — | 2 job openings · 1 award |
| 31 | DermBiont Developer of microbial therapeutics designed to treat skin diseases | $73M | 32 mo ago | 36 | 2015 | Nichola Eliovits Co-Founder | 49 patents Topical PK/AKT inhibitor formulations for treating and preventing skin disorders | — |
| 32 | DeepCure AI-driven drug discovery platform for inflammation & immunology space | $72M | 26 mo ago | 22 22 → 27 (+23%) · sector median +0% | 2018 | Kfir Schreiber Co-Founder & CEO | 10 patents AI-driven drug discovery and automated chemical synthesis workflow optimization | — |
| 33 | Naveris Provider of blood tests for early cancer detection | $69M | 24 mo ago | 53 | 2017 | Piyush Gupta Founder & CEO | — | — |
| 34 | Kytopen Developer of gene delivery systems for cell therapy 50Funding top 21%Talent top 28%Moat top 32%Patents top 33% All 8 signals ▾Fundingtop 21% Talenttop 28% Moattop 32% Patentstop 33% Innovationtop 36% Globalbottom 40% Marketbottom 28% Newsbottom 22% Funding: Raised $43.1M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $43M | 2 mo ago | 12 12 → 27 (+125%) · sector median +0% | 2017 | Cullen Buie Co-Founder | 31 patents Automated electro‑mechanical transfection systems for gene and cell delivery | — |
| 35 | Solarea Bio Innovating microbial solutions for human health, focusing on aging well 29Funding top 29%Moat top 39%Tech top 43%News top 44% All 7 signals ▾Fundingtop 29% Moattop 39% Techtop 43% Newstop 44% Talentbottom 49% Globalbottom 36% Marketbottom 29% Funding: Raised $27.3M across 4 rounds · 4 rounds over 9 yrs (0.4/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 29/100 | $27M | 7 mo ago | 24 | 2017 | Gerardo Toledo Co-Founder & CEO | — | — |
| 36 | seqWell Provider of NGS-based reagents and kits for life sciences research | $21M | 21 mo ago | 38 38 → 38 (+0%) · sector median +0% | 2014 | Jack Leonard Co-Founder & CTO | 27 patents Nucleic acid library preparation, normalization, and engineered transposase tools for NGS. | 2 launchs |
| 37 | Fluent BioSciences Developer of reagent for DNA analysis for genetic analysis | $19M | 16 mo ago | 48 | 2018 | Sepehr Kiani Founder & CEO & President | 145 patents Microfluidic droplet platforms for single‑cell and multi‑omic analysis of biomolecules. | — |
| 38 | 4D Path Developer of precision medicines for the treatment of cancer 35Talent top 28%Patents top 31%Funding top 37%Moat top 38% All 8 signals ▾Talenttop 28% Patentstop 31% Fundingtop 37% Moattop 38% Innovationtop 41% Techbottom 38% Globalbottom 37% Marketbottom 23% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Patents: 46 patents matched (strict assignee match) · 15 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $17M | 1 mo ago | 10 | 2016 | Rodrigo Navarro Co-Founder & CEO & President | 46 patents Lipid‑nanoparticle delivery systems for malaria vaccines and encapsulated therapeutics | 1 partnership |
| 39 | Genialis Developer of end-to-end bioinformatics software solutions 53Funding top 33%Growth top 35%Moat top 37%Patents top 38% All 10 signals ▾Fundingtop 33% Growthtop 35% Moattop 37% Patentstop 38% Innovationtop 39% Talenttop 41% Producttop 46% Techtop 50% Globalbottom 44% Marketbottom 35% Funding: Raised $15.3M across 6 rounds · 6 rounds over 11 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $15M | 6 mo ago | 35 | 2015 | Rafael Rosengarten Chief Executive Officer | 17 patents Patents concentrated in computing, sensing & instrumentation | 1 launch |
| 40 | Aquinnah Pharmaceuticals Developer of therapeutics to modulate neurodegenerative stress granules | $15M | 15 mo ago | 4 | 2006 | — | — | — |
| 41 | Transcode Therapeutics Developer of mRNA therapeutics to treat cancer | $13M | 18 mo ago | 19 19 → 16 (-16%) · sector median +0% | 2015 | — | — | — |
| 42 | MarvelBiome Developer of novel therapeutics using microbiome | $13M | 8 mo ago | 9 | 2019 | Priti Chatter Co-Founder | 87 patents Therapeutic microbiome formulations for metabolic, neurodegenerative, and longevity applications. | — |
| 43 | EnPlusOne Bio Developer of RNA synthesis platform for gene therapeutics | $12M | 18 mo ago | 9 | 2022 | Daniel Ahlstedt Co-founder and Chief Operating Officer | — | — |
| 44 | Hunterian Provider of gene-editing platform based on CRISPR delivery technology | $8M | 16 mo ago | 6 | 2004 | Vinod Ranga Founder & CEO | — | — |
| 45 | Tiba Biotech Provider of fully synthetic RNA vaccine drug delivery technology | $6M | 9 mo ago | 16 | 2017 | Christian W Mandl Co-Founder | 58 patents Patents concentrated in health & consumer products | — |
| 46 | Remedium Bio Developer of gene therapies for a broad range of diseases 7Funding top 37%Moat top 48%Global bottom 36%Tech bottom 22% All 5 signals ▾Fundingtop 37% Moattop 48% Globalbottom 36% Techbottom 22% Marketbottom 20% Funding: Raised $5.6M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 7/100 | $6M | 1 mo ago | 5 | 2020 | — | — | 1 job opening |
| 47 | Portal Provider of cell engineering and cell analytics across research and clinical applications | $5M | 18 mo ago | — | 2023 | Armon Sharei Founder & CEO | 22 patents AI agent orchestration platform with context enrichment and user-agent verification | — |
| 48 | InnoTech Precision Medicine Developer of multimodal molecular diagnostic platform for early disease detection | $3M | 10 mo ago | 5 | 2021 | Reza Mollaaghababa Co-Founder | — | 1 internship · 1 launch |
| 49 | Canal Biosciences Developer of library preparation technology for next generation sequencing workflows | $2M | 3 mo ago | — | 2024 | Yu Zheng Founder & Co-CEO | — | — |
| 50 | Factor Bioscience Developer of genomic technologies to treat disease and improve health | $1M | 9 mo ago | 10 | 2011 | Christopher Rohde Co-Founder & CTO | 289 patents Patents concentrated in chemistry & materials | — |
Top 12 Genomics companies in Massachusetts
#1
Public · Cambridge, Massachusetts · founded 2014 · 101 employees$92.5Mraised▾
Public · Cambridge, Massachusetts · founded 2014 · 101 employees
Developer of gene therapy platform for Duchenne muscular dystrophy. The lead candidate SGT-001 is Microdystrophin, a synthetic version of the dystrophin gene which stabilizes the muscle membrane and dystrophin-glycoprotein complex. Also, developed a soft wearable device for mobility and help preserve muscle function.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Patents
top 20%Funding
top 24%Innovation
top 31%Tech
top 33%Moat
top 38%News
top 48%Patents: 60 patents matched (strict assignee match) · 43 filings since 2022 vs 17 in 2017-21 · Latest publication 2026
Funding: Raised $92.5M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) · Last round Post IPO (Mar 2026)
Innovation: 60 patents (top 27% of patent-holders) · 43 filings since 2022 vs 17 in 2017-21
Funding rounds
- Mar 2026Post IPO$240M
- Jan 2024Post IPO$108.9M
- Dec 2020Post IPO$90M
- Oct 2020Post IPO$40M
Investors
RA Capital Management, RTW Investments, Foresite Capital, Perceptive Advisors, Janus Henderson Investors, Biogen
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#2
Series B · Cambridge, Massachusetts · founded 2017 · 12 employees$43.1Mraised▾
Series B · Cambridge, Massachusetts · founded 2017 · 12 employees
Developer of gene delivery systems for cell therapy. The proprietary non-viral flowfect technology combines electric fields and continuous fluid flow to engineer cells by delivery of payloads such as mRNA, DNA, and CRISPR Cas9 RNP to primary cells. The platform has applications in the discovery and manufacturing of cell and gene therapies.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 21%Talent
top 28%Moat
top 32%Patents
top 33%Innovation
top 36%Global
bottom 40%Funding: Raised $43.1M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) · Last round Series B (Apr 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 7/10 · IP moat: 31 patents · 9 curated direct competitors tracked
Audience (LinkedIn): 7k LinkedIn followers
Funding rounds
- Apr 2026Series B—
- Apr 2025Grant (prize money)$1.4M
- Feb 2025Grant (prize money)$1.4M
- Aug 2024Grant (prize money)$1.6M
Founders & team
Investors
MassVentures, Horizons Ventures, Engine Ventures, NIAID, America’s Seed Fund, Alexandria
#3
Series C · Cambridge, Massachusetts · founded 2016 · 117 employees$300Mraised▾
Series C · Cambridge, Massachusetts · founded 2016 · 117 employees
Provider of genomic technologies and drug discovery platform. This platform employs a diverse set of technologies and techniques including artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening for enabling the discovery of proteins. The company has also identified a new CRISPR enzyme using its discovery platform.
Fliar Intelligence Index™ 82how this company ranks against its industry peers
Patents
top 15%Innovation
top 17%Funding
top 19%Growth
top 25%Product
top 25%Moat
top 26%Patents: 372 patents matched (strict assignee match) · 307 filings since 2022 vs 65 in 2017-21 · Latest publication 2026
Innovation: 372 patents (top 6% of patent-holders) · 307 filings since 2022 vs 65 in 2017-21 · 4 product lines
Funding: Raised $300M across 3 rounds · 3 rounds over 9 yrs (0.3/yr) · Last round Series C (Oct 2025)
Audience (LinkedIn): 17k LinkedIn followers — 2.9% of this cohort's audience
Activity (LinkedIn): 2 partnerships (incl. Department of Health Abu Dhabi) announced in 12 mo
Funding rounds
- Oct 2025Series C—
- Mar 2025Series C$73.5M
- Nov 2021Series B$215M
- Aug 2017Series A$15.6M
Founders & team
Investors
Temasek, TCG Crossover, Arch Venture Partners, Ally Bridge Group, ArrowMark Partners, GreatPoint Ventures
Tech stack
WordpressMysqlPhpWordpress Super CacheContact Form 7Yoast Seo
#4
Public · Cambridge, Massachusetts · founded 2017 · 140 employees$165Mraised▾
Public · Cambridge, Massachusetts · founded 2017 · 140 employees
Tango Therapeutics is a biotech company developing novel drugs for the treatment of cancer. The company uses DNA sequencing and CRISPR-based screening to identify targets for specific subgroups of cancer patients. The company is discovering novel targets using synthetic lethality, where the cancer-causing alteration in a tumour suppressor gene creates a vulnerability that leads to the destruction of the tumour cell.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 21%News
top 21%Growth
top 24%Talent
top 33%Fin. health
top 41%Tech
top 44%Funding: Raised $165M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) · Last round Post IPO (Oct 2025)
News: 17 BI events in 12 mo (of 35 tracked, 6 types) · +240% YoY · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo
Growth: Headcount 110 → 140 (+27%) across vintages · Revenue +48% YoY · Web rank 10,000,000 → 5,000,000 YoY
Audience (LinkedIn): 24k LinkedIn followers — 4.1% of this cohort's audience
Funding rounds
- Oct 2025Post IPO$15M
- Aug 2023Post IPO$80M
- Aug 2020Series B$50M
- Apr 2020Series B$60M
Founders & team
Investors
Casdin Capital, Boxer Capital, Third Rock Ventures, Gilead, Tavistock Group, Roche
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#5
Public · Cambridge, Massachusetts · founded 2018 · 62 employees$179.6Mraised▾
Public · Cambridge, Massachusetts · founded 2018 · 62 employees
Provider of a drug prediction and development tool for researchers. The platform helps to code the discrete set of combinatorial rules used by any human cell type central to disease pathology. It uses machine learning algorithms to solve for druggable targets to control the output of any disease gene of interest.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 17%Growth
top 37%Moat
top 39%Talent
top 41%AI
top 45%Market
bottom 41%Funding: Raised $180M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) · Last round Post IPO (Sep 2025)
Growth: Headcount 37 → 62 (+68%) across vintages · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 6/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 9k LinkedIn followers
Funding rounds
- Sep 2025Post IPO$100M
- Jun 2022Series B$100.5M
- Mar 2021Series B$45M
- Apr 2018Series A$34.1M
Founders & team
Investors
Enavate Sciences, 5AM Ventures, Polaris Partners, Northpond Ventures, Andreessen Horowitz, Gaingels
Tech stack
Apple Icloud MailCookieyesCore-JsDocusignFlywheelGodaddy
#6
Series B · Boston, Massachusetts · founded 2016 · 10 employees$17.1Mraised▾
Series B · Boston, Massachusetts · founded 2016 · 10 employees
4D Path is a developer of precision medicines for the treatment of cancer. It has developed medicines for cancer diagnosis and it provides therapeutic molecular overexpression profiles. It has developed precision diagnostics solutions that help in identify cancer types, subtypes, variants & mimics, surgical margin, and others.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Talent
top 28%Patents
top 31%Funding
top 37%Moat
top 38%Innovation
top 41%Tech
bottom 38%Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Patents: 46 patents matched (strict assignee match) · 15 filings since 2022 vs 13 in 2017-21 · Latest publication 2025
Funding: Raised $17.1M across 2 rounds · 2 rounds over 6 yrs (0.3/yr) · Last round Series B (May 2026)
Audience (LinkedIn): 1k LinkedIn followers
Activity (LinkedIn): 2 partnerships (incl. VCTS) announced in 12 mo
Funding rounds
- May 2026Series B—
- May 2023Series B$13M
- Jul 2020Series A$4.1M
Founders & team
Tech stack
AosAzureBootstrapCdnjsCloudflareCookieyes
#7
Series B · Cambridge, Massachusetts · founded 2016 · 38 employees$143.5Mraised▾
Series B · Cambridge, Massachusetts · founded 2016 · 38 employees
QurAlis is engaged in discovering and developing new therapies for amyotrophic lateral sclerosis (ALS), which is a common form of motor neuron disease. The company has developed Optopatch technology which helps in stimulating the neurons and notes their electrical behavior. Their proprietary method clears toxic proteins and transcranial magnetic stimulation helps in diagnosing ALS by identifying biomarkers such as protein in the blood. In addition, other therapeutic targets like nerve threshold tracking, proteins in the cerebral spinal fluid helps to predict ALS. The company has a preclinical-stage program for ALS drugs targeting the Kv7.2/7.3 channel & CSF cartridge device to remove DPR proteins.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 20%Patents
top 23%Innovation
top 25%Growth
top 26%Moat
top 32%Talent
top 41%Funding: Raised $144M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) · Last round Series B (Aug 2025)
Patents: 69 patents matched (strict assignee match) · 62 filings since 2022 vs 7 in 2017-21 · Latest publication 2026
Innovation: 69 patents (top 25% of patent-holders) · 62 filings since 2022 vs 7 in 2017-21
Audience (LinkedIn): 13k LinkedIn followers — 2.2% of this cohort's audience
Funding rounds
- Aug 2025Series B$20M
- Mar 2023Series B$88M
- Sep 2022Grant (prize money)$300K
- Jul 2020Grant (prize money)$107.4K
Founders & team
Investors
Polaris Partners, Mission BioCapital, MP Healthcare Venture Management, Dolby Family Ventures, SV Health Investors, Droia Ventures
Tech stack
AccessibeApple Icloud MailCloudflareCloudflare Bot ManagementCookieyesGenesis Blocks
#8
Series A · Needham, Massachusetts · founded 2020 · 5 employees$5.6Mraised▾
Series A · Needham, Massachusetts · founded 2020 · 5 employees
Developer of gene therapies for a broad range of diseases. The company is developing a pipeline of a broad range of therapies for immune and age-related conditions which includes RMD 1101 for rheumatology, RMD 1202 for endocrinology, RMD 1501 for neurology, and RMD 1201 for Type-1 diabetes.
Fliar Intelligence Index™ 7how this company ranks against its industry peers
Funding
top 37%Moat
top 48%Global
bottom 36%Tech
bottom 22%Market
bottom 20%Funding: Raised $5.6M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) · Last round Series A (May 2026)
Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked
Global: Investors from 2 countries beyond United States
Audience (LinkedIn): 3k LinkedIn followers
Hiring (LinkedIn): 7 hiring posts in 12 mo (public) · momentum -2 · hiring: Research Associate, Scientist/Senior Scientist, Molecular Biology
Activity (LinkedIn): 1 partnerships (incl. Lilly) announced in 12 mo
Funding rounds
- May 2026Series A$1.5M
- Sep 2024Seed—
- Aug 2023Grant (prize money)$275K
- Aug 2022Seed$2.3M
Investors
LifeSpan Vision Ventures, Sherwood Ventures, Longevitytech.fund, Primo Medical Group, Angel Star Ventures, APIS Health Angels
#9
Public · Lexington, Massachusetts · founded 2008 · 287 employees$215.1Mraised▾
Public · Lexington, Massachusetts · founded 2008 · 287 employees
Developer of a platform for RNA-based products for the life science industry. It offer platform that is used for vaccine development, antibody therapies, pandemic preparation, crop management, plant protection, support the health of bees and other pollinators
Fliar Intelligence Index™ 69how this company ranks against its industry peers
Funding
top 23%Growth
top 23%Patents
top 24%Innovation
top 29%Talent
top 41%Moat
top 42%Funding: Raised $215M across 12 rounds · 12 rounds over 13 yrs (0.9/yr) · Last round Post IPO (Apr 2025)
Growth: Headcount 163 → 287 (+76%) across vintages · Revenue +325% YoY · Web rank 5,000,000 → 10,000,000 YoY
Patents: 311 patents matched (strict assignee match) · 125 filings since 2022 vs 128 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 25k LinkedIn followers — 4.4% of this cohort's audience
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- Apr 2025Post IPO$25M
- Jul 2024Grant (prize money)$174.3K
- Mar 2024Grant (prize money)$325.1K
- Aug 2022Post IPO$109M
Founders & team
Investors
Serum Life Sciences, Flu Lab, Xeraya Capital, Baird Capital, Continental Grain Company, Tao Capital Partners
Tech stack
CloudflareGoogle AnalyticsGoogle Font ApiGoogle Hosted LibrariesGoogle Tag ManagerHsts
#10
Acquired · Watertown, Massachusetts · founded 2019 · 33 employees$111Mraised▾
Acquired · Watertown, Massachusetts · founded 2019 · 33 employees
Provider of a diagnostic platform for DNA and RNA detection. The company has developed proprietary CRISPR-based SHERLOCK and synthetic biology-based INSPECTR technologies to create diagnostic tools for the detection of infectious disease, early detection of cancer, treatment monitoring, and precision medicine.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Growth
top 13%Funding
top 22%Talent
top 28%Moat
top 41%Patents
bottom 46%Innovation
bottom 41%Growth: Headcount 1 → 33 (+3200%) across vintages · Fresh capital in last 24 mo
Funding: Raised $111M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) · Last round Grant (prize money) (Jun 2025)
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Funding rounds
- Jun 2025Grant (prize money)$130.3K
- Aug 2024Grant (prize money)$298.9K
- Jul 2023Grant (prize money)$175K
- Nov 2022Grant (prize money)$2M
Founders & team
Investors
Open Philanthropy, Novalis LifeSciences, Illumina Ventures, Albany Capital, Good Ventures, Northpond Ventures
#11
Series B · Cambridge, Massachusetts · founded 2017 · 47 employees$103.1Mraised▾
Series B · Cambridge, Massachusetts · founded 2017 · 47 employees
Provider of a platform to deliver mRNA therapeutics for multi-functional treatments. The programming platform detects the location and enhances the cell type protein expression in the patient's body to optimize the immunotherapy treatments.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Growth
top 13%Funding
top 24%Moat
top 31%News
top 41%Talent
top 41%Global
bottom 39%Growth: Headcount 16 → 47 (+194%) across vintages · Fresh capital in last 24 mo
Funding: Raised $103M across 6 rounds · 6 rounds over 7 yrs (0.9/yr) · Last round Series B (May 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 27k LinkedIn followers — 4.8% of this cohort's audience
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- May 2025Series B$153M
- Nov 2022Series A$45M
- Jun 2021Series A$52.1M
- May 2021Grant (prize money)$399.5K
Founders & team
Investors
Playground Global, Alexandria, ANRI, Redmile Group, BeiGene, Camford Capital
#12
Series A · Boston, Massachusetts · founded 2015 · 35 employees$15.3Mraised▾
Series A · Boston, Massachusetts · founded 2015 · 35 employees
Developer of end-to-end bioinformatics software solutions. It combines biomedical data management, customizable data analysis pipelines, and interactive visualizations. Its platform is a complete data ecosystem, a solution for sequencing data management, analysis, visualization, and dissemination. It claims that this platform can be easily configured locally or on the cloud and also offers web-based software that automates data management and analysis tasks.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 33%Growth
top 35%Moat
top 37%Patents
top 38%Innovation
top 39%Talent
top 41%Funding: Raised $15.3M across 6 rounds · 6 rounds over 11 yrs (0.5/yr) · Last round Series A (Dec 2025)
Growth: Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 7/10 · IP moat: 17 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 5k LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Dec 2025Series A$700K
- Jan 2023Series A$13M
- Oct 2021Grant (prize money)—
- Nov 2017Seed$2.3M
Founders & team
Investors
Redalpine, First Star Ventures, Pikas, Europa, Arrs, Taiwania Capital
Tech stack
Amazon SesAmazon Web ServicesApple Icloud MailBootstrapCloudflareCloudflare Bot Management
Funding & investor landscape
$18.1Btotal disclosed funding
212companies funded
815disclosed rounds
3rounds last 90 days
Most active investors
Atlas Venture14 rounds
Notable founders
Cullen Buie
Co-Founder · Kytopen
Paulo Garcia
Co-Founder · Kytopen
David Scott
Co-Founder · Arbor Biotechnologies
Winston Yan Md
Co-Founder · Arbor Biotechnologies
Barbara Weber Md
President and CEO · Tango Therapeutics
Josh Mandel-Brehm
CEO · CAMP4
Rodrigo Navarro
Co-Founder & CEO & President · 4D Path
Supratim Ray
Co-Founder & CIO · 4D Path
Kasper Roet
Founder & CEO · QurAlis
Andrey Zarur
Co-Founder & CEO · GreenLight Biosciences
David Walt
Co-Founder · Sherlock
Omar Abudayyeh
Co-Founder · Sherlock
Prism market signals · United States · country-scoped Prism corpus, 1,273,702 docs
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN MASSACHUSETTS · Health & Bio
How research on Bioinformatics in Massachusetts is moving
A read on the academic research around Bioinformatics in Massachusetts — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 421 papers.
MIT, MGH, and UMass Chan lead Massachusetts bioinformatics research, predominantly advancing single-cell transcriptomics and CRISPR with a cautiously optimistic tone (mean stance 0.51).
421 papers · stance +0.51 · 58% breakthrough · 16% concern
top institutions
- Massachusetts General Hospital161
- Massachusetts Institute of Technology154
- University of Massachusetts Chan Medical School56
- University of Massachusetts Amherst28
- Massachusetts Eye and Ear Infirmary14
leading researchers
Philipp Schneider · Radhika Subramanian · Rebecca Sanon · Sharon K. Marr · Stefan Niekamp · Harini Narayanan
prism intelligence · tone & topics
90% positive · 4% critical tone
BiotechnologyMedical ResearchPharmaceuticalsHealthGeneticsBiology
▲
Breakthroughs199 · 47%
▼ 53%→45% share
▼0.8× share momentum0 median citations71% since 2021mostly methods-led
Cell and Workflow sub-topics newly emerged (7 and 6 papers), while Disease research surged 1→10, signaling rapid pipeline diversification.
rising sub-themes (early→recent)
- Disease1→10
- Chromatin2→9
- Transcriptome3→9
- Gene9→15
- Identification (biology)2→6
Newly emergingCell 0→7 · Workflow 0→6 · Modular design 0→6
Landmark The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data · 29,447 cites
◆
Advancements92 · 22%
▲ 14%→25% share
▲1.8× share momentum0 median citations86% since 2021mostly empirical
Advancements field-share nearly doubled (14%→25%); Transcriptome and Immune system newly emerged at 7 and 6 papers respectively.
rising sub-themes (early→recent)
- Disease1→9
- Epigenetics1→5
- Gene3→6
Newly emergingTranscriptome 0→7 · Immune system 0→6 · Cognition 0→6
Landmark Predicting effective microRNA target sites in mammalian mRNAs · 7,559 cites
▼
Concerns54 · 13%
▼ 19%→11% share
▼0.6× share momentum0 median citations65% since 2021mostly reviews
Concerns field-share contracted 19%→11%, yet Immunotherapy and Synthetic biology newly emerged, flagging fresh biosafety scrutiny areas.
rising sub-themes (early→recent)
- Disease2→6
- Cancer1→3
Newly emergingImmunotherapy 0→4 · Synthetic biology 0→3 · Biomarker 0→3
Landmark The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia · 10,090 cites
Common questions
How many Genomics companies are there in Massachusetts, United States?
Radar tracks 307 indexable Genomics companies headquartered in Massachusetts, United States that meet our profile-completeness bar.
What is the total funding raised by Genomics companies in Massachusetts, United States?
The Genomics companies in Massachusetts, United States on this list have raised a combined $18.1B in disclosed equity funding across 212 funded companies.
Which is the highest-funded Genomics company in Massachusetts, United States?
ElevateBio is the highest-funded Genomics company in Massachusetts, United States, with $1.2B in disclosed equity funding.
How many Genomics companies in Massachusetts, United States are funded?
212 of the 307 Genomics companies in Massachusetts, United States on this list have disclosed at least one equity funding round.
How many Genomics unicorns are there in Massachusetts, United States?
3 Genomics companies in Massachusetts, United States on this list are valued at $1B or more.
Who are the top investors in Massachusetts, United States Genomics companies?
The most active investors in Massachusetts, United States Genomics companies on this list include HHS, Arch Venture Partners, Casdin Capital, Alexandria, Flagship Pioneering.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.